Lidoflazine
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | C08EX01 (WHO) |
| Identifiers | |
| |
| CAS Number |
3416-26-0  |
| PubChem (CID) | 3926 |
| ChemSpider |
3789  |
| UNII |
J4ZHN3HBTE |
| KEGG |
D04733 |
| ECHA InfoCard | 100.020.285 |
| Chemical and physical data | |
| Formula | C30H35F2N3O |
| Molar mass | 491.615 g/mol |
| 3D model (Jmol) | Interactive image |
| Melting point | 159 to 161 °C (318 to 322 °F) |
| Solubility in water | Almost insoluble in water(<0.01%); Very soluble in chloroform(>50%); mg/mL (20 °C) |
| |
| |
| (what is this?) (verify) | |
Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action.[1] Lidoflazine was discovered at Janssen Pharmaceutica in 1964.
Physical properties
Solubility at room temperature
Extracted from [2]
| Solvent | 0.01
N |
0.1
N | ||
| % | pH | % | pH | |
| Hydrochloric Acid | 0.4 | 3.0 | 0.7 | 1.9 |
| Tartaric Acid | 0.3 | 3.1 | 1.0 | 2.5 |
| Citric Acid | 0.3 | 3.1 | 0.5 | 2.5 |
| Lactic Acid | 0.2 | 3.4 | 0.7 | 2.9 |
| Acetic Acid | 0.1 | 3.5 | 0.4 | 3.8 |
References
- ↑ Schaper, W.K.A.; Xhonneux, R.; Jageneau, A.H.M.; Janssen, P.A.J. (1966). "The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator". Journal of Pharmacology and Experimental Therapeutics. 152 (2): 265–274. PMID 5944369. Retrieved 2009-06-20.
- ↑ http://jpet.aspetjournals.org/cgi/content/abstract/152/2/265
- Schaper WK, Xhonneux R, Jageneau AH., Stimulation of the coronary collateral circulation by lidoflazine (R 7904), Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965 November 4;252(1):1-8.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.